EC
CYTK icon

EntryPoint Capital’s Cytokinetics CYTK Stock Holding History

EntryPoint Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,586
Closed -$218K – 718
2025
Q2 		$218K Sell
6,586
-254
-4% -$8.84K 0.11% 447
2025
Q1 		$275K Sell
6,840
-4,083
-37% -$188K 0.13% 370
2024
Q4 		$514K Buy
10,923
+2,098
+24% +$109K 0.22% 96
2024
Q3 		$466K Buy
+8,825
New +$492K 0.27% 72
2024
Q2 		– Sell
-1,050
Closed -$73.6K – 1042
2024
Q1 		$73.6K Buy
+1,050
New +$81.2K 0.07% 574

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

EntryPoint Capital's CYTK Position: Q3 2025 in Review

EntryPoint Capital sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 6,586 shares — an estimated $218K sold.

EntryPoint Capital first reported a position in CYTK in Q1 2024 and held it in 5 quarters. The position peaked at $514K in Q4 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • EntryPoint Capital reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • EntryPoint Capital sold 6,586 Cytokinetics shares in Q3 2025, an estimated $218K.
  • EntryPoint Capital first reported a position in Cytokinetics in Q1 2024 and held it in 5 quarters.
  • EntryPoint Capital's Cytokinetics position peaked at $514K in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.